comprehensive -WSS

comprehensive

author：entertainment 2025-10-08 16:06:33 - browse：68

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Listen: Biogen's messy board & Laronde's data problem

leisure time

WSS

Idaho college killings prosecutors challenge defense's grand jury claims

What to know about the judge who will handle the Trump case

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

Option Care buys Amedisys in $3.6 billion home care deal

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

YouTube cracks down on misinformation on cancer treatment

focus

comprehensive

hotspot

Psychedelics group wrestles with new pharma identity

Make 'food is medicine' a key part of White House nutrition meeting

Medical records are filled with copy

Brain 'hot spot' may explain why African Americans feel greater pain

Hepatitis C has a cure — but many Americans still lack access to it

Doctor appointment wait times are getting worse

Peter Hotez and the public health issue of online harassment

Listen: Biogen's messy board & Laronde's data problem

Trump demands the U.S. pay no more for drugs than other countries … again

Pfizer's Covid pill remains 89% effective in final analysis, company says

Wikipedia

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Connecting traumatic brain injury and domestic violence

Van's Gluten Free Original Waffles recalled for possible wheat allergen

Mark Cuban is blaming the wrong people for high drug costs

New case study details death in closely watched Alzhiemer's trial

Schizophrenia gene found to be linked to cells' energy dysfunction

knowledge

focus

leisure time

Wikipedia